Skip to main content

Nina Paulshus Sundlisæter

Postdoc
https://orcid.org/0000-0002-1295-0172
View Google Scholar profile
See publications in PubMed

Education

  • Cand.med at the University of Bergen
  • Specialist in rheumatology
  • Doctorate (PhD) at the Department of Clinical Medicine, University of Oslo

Position

  • Senior Consultant at the Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
  • Post doc, Clinic for Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital

Field of interest

  • Rheumatology
  • Outcome measures
  • Prediction
  • Follow-up and treatment
  • Randomized controlled trials

Email

Telephone

+47 22451500

Visiting address

Diakonhjemmet Hospital
Superintendent's residence
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet Hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP1 - Optimized medical interventions

ARCTIC

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

WP1 - Optimized medical interventions

ARCTIC REWIND

Study on tapering treatment in rheumatoid arthritis without loss of disease control.

WP1 - Optimized medical interventions

ARCTIC REWIND extension study

Long-term follow-up of patients with well-controlled rheumatoid arthritis - the ARCTIC REWIND extension study

WP5 - Innovative approaches to remote care

NOR-Flare

Remote follow-up of patients with rheumatoid arthritis

WP2 - PPhenotyping for personalized medicine

START

Early diagnosis of newly occurring arthritis

Publications

Publications retrieved from the National Science Archives (NVA):

Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis

2026

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

2025

Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study

2025

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

2023

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

2022

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

2021

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

2018

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

2017